[CAS NO. 90332-63-1] 10-Deacetyl-7-xylosylpaclitaxel

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [90332-63-1]

Catalog

AS993336

Brand

Arctom Scientific

CAS

90332-63-1

DESCRIPTION [90332-63-1]

Overview

MDL	-
Molecular Weight	943.98
Molecular Formula	C50H57NO17
SMILES	CC(O[C@]([C@@]1([H])C[C@@H]2O[C@@](OC[C@@H](O)[C@@H]3O)([H])[C@@H]3O)(CO1)[C@]([C@@H]([C@]4(C(C)(C)C5=C(C)[C@@H](OC([C@H](O)[C@H](C6=CC=CC=C6)NC(C7=CC=CC=C7)=O)=O)C4)O)OC(C8=CC=CC=C8)=O)([H])[C@@]2(C([C@@H]5O)=O)C)=O

For research use only. We do not sell to patients.

Summary

10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features. IC50 value: Target: Microtubule inhibitor 10-Deacetyl-7-xylosyl paclitaxel induced mitotic cell cycle arrest and apoptosis as measured by flow cytometry, DNA laddering, and transmission electron microscopy. Pro-apoptotic Bax and Bad protein expression was up-regulated and anti-apoptotic Bcl-2 and Bcl-XL expression down-regulated, which lead to a disturbance of the mitochondrial membrane permeability and to the activation of caspase-9. In turn, caspase-9 activated downstream caspases-3 and -6, but not caspase-8 . Bid was also activated by caspase-3. Reversely, treatment with a caspase-10-specific inhibitor could not protect PC-3 cells from 7-xylosyl-10-deacetyl-paclitaxel-triggered apoptosis . Moreover, 7-xylosyl-10-deacetylpaclitaxel had no effect on the expression of CD95 and NF-kappaB proteins, indicating that apoptosis was induced through the mitochondrial-dependent pathway in PC-3 cells.

IC50 & Target

Traditional Cytotoxic Agents

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL ( 35.31 mM ; Need ultrasonic)

H ₂ O : 1 mg/mL ( 1.06 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.0593 mL	5.2967 mL	10.5934 mL
5 mM	0.2119 mL	1.0593 mL	2.1187 mL
10 mM	0.1059 mL	0.5297 mL	1.0593 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.65 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Jiang S, et al. Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol. 2008 Jul;33(1):103-11.

Synonyms

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(β-D-xylopyranosyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(β-D-xylopyranosyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

10-Deacetyltaxol 7-xyloside

10-Deacetyl-7-xylosyltaxol

7-Xylosyl-10-deacetyltaxol

10-Deacetylpaclitaxel 7-xyloside

7β-Xylosyl-10-deacetyltaxol

10-Deacetyl-7-xylosylpaclitaxel

7-Xylosyl-10-deacetylpaclitaxel